COVID-19 Pandemisinde Meme Kanseri Hastalarının Cerrahi Yönetimi ve Pandemi Öncesi ile Erken Dönem Sonuçlarının Karşılaştırılması

Amaç: COVID-19 pandemisinde sağlık alanında kullanılan tüm ekipman ve personelin, pandemi hastalarının izolasyonu, tanı ve tedavileri için kullanılması gerekebilmektedir. Biz pandemi döneminde onkolojik hasta grubunda cerrahi tedavide bazı gecikmelerin yaşanmış olabileceğini düşünmekteyiz. Bu nedenle merkezimizde pandemi öncesinde ve pandemi döneminde meme kanseri tanısı ile opere edilen hastaların demografik ve klinikopatolojik özelliklerini karşılaştırmayı amaçladık. Gereç ve Yöntem: Çalışma Eskişehir Osmangazi Üniversitesi Hastanesi Genel Cerrahi Kliniğinde retrospektif olarak dizayn edildi. Pandemi ilanından 9 ay öncesi ve 9 ay sonrasını kapsayacak şekilde meme kanseri nedeniyle opere edilen tüm hastaların demografik ve klinikopatolojik verileri retrospektif olarak incelendi ve istatistiksel olarak karşılaştırıldı. Bulgular: Toplam 186 hasta çalışmaya dahil edildi. Pandemi grubunda neoadjuvan tedavi görmüş hastaların istatistiksel olarak anlamlı şekilde yüksek oranda olduğu görüldü (p =%0,005) (Tablo 1). Ayrıca tedavideki gecikmeleri saptamak için kullandığımız gruplar arasında evre ve tümör boyutu karşılaştırılması yapılmış, istatistiksel olarak anlamlı farklılık bulunamamıştır (p =0,724, p =0,233) (Tablo 1). Sonuç: Çalışmamızda meme kanseri hastalarında cerrahi tedavinin gecikmesine bağlı olarak, covid döneminde opere edilen hastalarda ilerlemiş hastalık bulguları olacağı beklenmesine karşın istatistiksel olarak anlamlı farklılık saptanmadı. Bu süreçte onkolojik meme cerrahisi sonuçlarımızın eski sonuçlara benzer olmasının nedeninin meme kanseri olgularında multidisipliner tedavi yaklaşımımız olduğunu düşünmekteyiz.

A Comparison of Surgical Management and Early Results of Breast Cancer Patients in COVID-19 Pandemia

Objective: All equipment and personnel used in the healthcare field during the COVID-19 pandemic may need to be used for the isolation, diagnosis and treatment of pandemic patients. So we think that there may have been some delays in surgical treatment in the oncological patient group during the pandemic period. For this reason, we aimed to compare the demographic and clinicopathological characteristics of patients who were operated with the diagnosis of breast cancer before and during the pandemic in our center. Material and Method: The study was retrospectively designed at Eskisehir Osmangazi University Hospital General Surgery Clinic. Demographic and clinicopathological data of all patients who were operated for breast cancer 9 months before and 9 months after the declaration of the pandemic were retrospectively analyzed and compared statistically. Results: A total of 186 patients were included in the study. In the pandemic group, patients who received neoadjuvant therapy were found to be statistically significantly higher (p =0.005%) (Table 1). In addition, tumor stage and tumor size were compared between the groups we used to detect delays in treatment, and no statistically significant difference was found (p =0.724, p =0.233) (Table 1). Conclusion: In our study, although it was expected that there would be signs of advanced disease in patients who were operated during the covid period due to the delay in surgical treatment in breast cancer patients, no statistically significant difference was found. We think that the reason why our oncological breast surgery results are similar to previous results is our multidisciplinary treatment approach in breast cancer cases.

PDF

___

1. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical beneft in breast cancer: The CTNeoBC pooled analysis. Lancet 2014; 384: 164-72.
2. American College of Surgeons COVID-19: guidance for triage of non-emergent surgical procedures. https://www.facs.org/covid-19/clinicalguidance/ triage 11.03.2020.
3. Novel Coronavirus (2019-nCoV) situation reports. https://www.who.int/emergencies/diseases/novelcoronavirus- 2019/situation-reports 16.05.2020.
4. Coronavirus Disease (COVID-19) events as they happen. https://www.who.int/emergencies/diseases/novelcoronavirus- 2019/events-as-they-happen 31.07.2020.
5. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol 2014; 15: e351-62.
6. Elanko A, Khan J, Hamady ZZ et al. Cancer surgery sustainability in the light of COVID-19 pandemic. Eur J Surg Oncol 2020; 46: 1174-5.
7. Tuech J-J, Gangloff A, Di Fiore F et al. Strategy for the practice of digestive and oncological surgery during the COVID-19epidemic. J Visc Surg 2020; 157: S7-12.
8. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama 2020; 18: 1775-6.
9. Rosenbaum L. Facing Covid-19 in Italy-ethics, logistics, and therapeutics on the epidemic’s front line. N Engl J Med 2020; 20: 1873-5.
10. Ahmed M, Anninga B, Goyal S et al. Magnetic sentinel node and occult lesion localization in breast cancer (MagSNOLL Trial). Br J Surg 2015; 102: 646-52.
11. Buonomo OC, Grasso A, Pistolese CA et al. Evaluation of concordance between histopathological, radiological and biomolecular variables in breast cancer neoadjuvant treatment. Anticancer Res 2020; 40: 281-6.
12. American College of Surgeons (ACS). COVID 19: Elective Case Triage Guidelines for Surgical Care. Available from: https://www.facs.org/covid- 19/clinical-guidance/ elective-case, accessed on 7th April 2020.
13. Zada A, Peek MC, Ahmed M et al. Meta-analysis of sentinel lymph node biopsy in breast cancer using the magnetic technique. Br J Surg 2016; 103: 1409-19.